Sarepta Therapeutics Inc (NAS:SRPT)
$ 121.5 -1.87 (-1.52%) Market Cap: 11.61 Bil Enterprise Value: 11.98 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 86/100

Sarepta Therapeutics Inc at RBC Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 06:30PM GMT
Release Date Price: $145.46 (-0.89%)
Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Good afternoon, everyone.

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Good afternoon, everyone, and thanks for joining us. It's Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. We're really pleased to have with us Sarepta Therapeutics, represented by their CEO, Doug Ingram. Doug, thanks so much for joining us.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you for having us, Brian.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

So a lot to cover in a short period of time, but maybe I'll kick it off with maybe one of the latest developments that we've seen in the DMD space which is an update on the gene therapy landscape that we've -- we saw last week. So I'd be interested, coming out of that, what your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot